Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
11,895.4523.35
Stock Analysis, IPO, Mutual Funds, Bonds & More

Lupin gets EIR from USFDA for Nagpur facility

USFDA conducted the inspection between August 5-8, 2019, Lupin said in a filing to the BSE.

PTI|
Oct 18, 2019, 04.01 PM IST
0Comments
BCCL
USFDA red flags Lupin for significant violations at MP unit
The Nagpur facility is the company's largest and most advanced oral solid dosage facility and has maintained a solid track record of compliance, Lupin said.
New Delhi: Drug major Lupin on Friday said it has received an establishment inspection report (EIR) from the US health regulator after inspection of its Nagpur facility in Maharashtra.

The United States Food and Drug Administration (USFDA) conducted the inspection between August 5-8, 2019, Lupin said in a filing to the BSE.

The inspection for the oral solid facility closed without any Form 483 observation, it added. Form 483 notifies the company's management of objectionable conditions.

The Nagpur facility is the company's largest and most advanced oral solid dosage facility and has maintained a solid track record of compliance, Lupin said.

"Excelling at quality and compliance is one of our top priorities and we remain committed to meeting and exceeding standards set by regulatory agencies globally," Lupin MD Nilesh Gupta said.

Shares of Lupin were trading at Rs 740.30 per scrip on BSE, up 1.91 per cent from the previous close.

Also Read

Aurobindo Pharma tanks on USFDA observations

Aurobindo Pharma under USFDA scrutiny

Alembic Pharma gets USFDA nod for Desonide Ointment

Aurobindo Pharma, Glenmark crack on USFDA observations

Comments
Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.

Other useful Links


Follow us on


Download et app


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service